Highlights

  • CurveBeam AI (ASX:CVB) develops weight-bearing CT imaging systems for orthopaedic applications.
  • The company received US regulatory clearance for CT-based bone mineral density software.
  • HiRise combines imaging hardware with software capabilities designed for bone assessment.
  • Commercial growth, regulatory progress and funding remain key areas to monitor.

CurveBeam AI Limited (ASX:CVB) is a medical imaging company focused on technologies that assess bones and joints under natural weight-bearing conditions. Its HiRise system is designed as a weight-bearing computed tomography (CT) scanner that captures images while patients stand.

The company combines imaging hardware with software tools aimed at supporting clinical analysis. The technology is focused on orthopaedic applications involving areas such as feet, ankles, knees and hands.

Regulatory Progress and Bone Mineral Density Software

In September 2026, CurveBeam reported US Food and Drug Administration 510(k) clearance for CT-based bone mineral density software using multidetector CT scans. The clearance allows quantitative measurement of bone density from CT images taken with patients in a non-weight-bearing position.

The company has indicated plans to pursue further regulatory progress to extend bone mineral density measurement capabilities to the HiRise weight-bearing platform. Such developments form part of CurveBeam’s broader software strategy.

Commercial Development and Market Expansion

CurveBeam continues to develop its commercial base through sales of imaging systems. During the fourth quarter of financial year 2026, the company reported customer receipts of approximately A$2.58 million and full-year FY2026 receipts of approximately A$7.78 million.

The company also reported HiRise purchase orders and continued engagement in international markets, including China through its commercialisation Partnership activities.

Funding and Execution Considerations

Like many medical technology companies expanding commercial operations, CurveBeam is managing the balance between growth Investment and available resources. The company reported cash of approximately A$1.64 million at 30 June 2026, increasing to a pro-forma position after a Capital raising.

Future progress depends on converting regulatory milestones and customer interest into sustainable commercial activity while managing operating requirements.

Key Insights

CurveBeam AI is building a medical imaging platform that combines specialised CT hardware with software capabilities. The company’s next stage will depend on commercial adoption, regulatory expansion and the ability to support ongoing technology development.